Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-02-2022 | Angiography | Medical Ophthalmology

Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT

Authors: Chiara Del Noce, Matilde Roda, Lorenzo Ferro Desideri, Carlo E. Traverso, Aldo Vagge

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2022

Abstract

Purpose

The aim of this study is to evaluate the changes in macular blood flow index (BFI) in patients with moderate to severe thyroid-associated orbitopathy (TAO) before and after pulse therapy and their relationship with clinical features and disease activity using angio-OCT technology.

Methods

We analyzed twenty-four eyes. Every patient underwent a complete eye examination and angio-OCT analysis (OCT Topcon ImageNet 6; DRI OCT Triton, Topcon Corporation) before (T0) and two months (T2) after pulse therapy. We analyzed macular vascular blood flow in four angiographic levels: superficial plexus (SP), deep plexus (DP), external retina (ER), and choriocapillaris (CC). We used the clinical activity score (CAS) score to define TAO as moderate or severe.

Results

Macular BFI significantly increased at T2 in the DP, ER, and CC (p < 0.01). CAS score (5.8 ± 0.8 vs. 3.9 ± 0.9, p < 0.01) and Hertel exophthalmometry values (22.6 ± 2.3 mm vs. 21.2 ± 2,5 mm, p < 0.01) improved for all patients at T2 compared T0. Mean IOP increased from 13.3 ± 2.8 mmHg to 14.3 ± 2.1 mmHg (p < 0.01). No correlation was found between CAS score and macular BFI in all the analyzed levels.

Conclusions

Pulse therapy treatment can change macular BFI. In particular, two months alter pulse therapy, all the patients show an increase in macular vascular blood flow in each angiographic level. According to our results, angio-OCT analysis of the macular BFI may be a useful tool in the follow-up of TAO patients after pulse therapy.

Bahn Chair RS, Burch HB, Cooper DS et al (2011) American Thyroid Association and American Association of Clinical Endocrinologists Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646CrossRef

Wemeau JL, Klein M, Sadoul JL, Briet C, Velayoudom-Cephise FL (2018) Graves’ disease: introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris) 79(6):599–607. https://doi.org/10.1016/j.ando.2018.09.002CrossRef

Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L et al (2013) J Clin Endocrinol Metab. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center 98:1443–1449. https://doi.org/10.1210/jc.2012-3873CrossRef

Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marocci C et al (2008) Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18(3):333–346CrossRef

Li Q, Ye H, Ding Y et al (2017) Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS ONE 12(5):e0176064. https://doi.org/10.1371/journal.pone.0176064CrossRefPubMedPubMedCentral

Bartley GB, Fatourechi V, Kadrmas EF et al (1996) Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121(3):284–290. https://doi.org/10.1016/s0002-9394(14)70276-4CrossRefPubMed

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) European Group on Graves O. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285CrossRef

Hodgson NM, Rajaii F (2020) Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. Ophthalmology and therapy. 9(1):21–33. https://doi.org/10.1007/s40123-019-00226-9CrossRefPubMed

Douglas RS, Gupta S (2011) The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 22(5):385–390. https://doi.org/10.1097/ICU.0b013e3283499446CrossRefPubMedPubMedCentral

10.

Coutinho Agnes E, Chapman Karen E (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 335(1):2–13. https://doi.org/10.1016/j.mce.2010.04.005CrossRefPubMedPubMedCentral

11.

Phillips ME, Marzban MM, Kathuria SS (2010) Treatment of thyroid eye disease. Curr Treat Options Neurol 12:64–69. https://doi.org/10.1007/s11940-009-0054-0CrossRefPubMed

12.

Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC. J (2015) Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015:249125. https://doi.org/10.1155/2015/249125

13.

Fells P (1991) Thyroid-associated eye disease: clinical management. Lancet 338:29–32CrossRef

14.

Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K (1988) Intravenous methyl-prednisolone in the treatment of Graves’ ophthalmopathy. Br Med J 297:1574–1578CrossRef

15.

Marcocci C, Bartalena L, Tanda ML et al (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:35627

16.

Walasik-Szemplińska D, Kamiński G, Sudoł-Szopińska I (2019) Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy. Thyroid Res. 12:13. https://doi.org/10.1186/s13044-019-0074-0CrossRefPubMedPubMedCentral

17.

Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:32032CrossRef

18.

Bartalena L, Krassas GE, Wiersinga W et al (2012) European Group on Graves’ Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97:445463

19.

Sisti E, Coco B, Menconi F et al (2015) Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy. Thyroid 25:84650CrossRef

20.

Kahaly GJ. (2010) Management of moderately severe Graves’ orbitopathy In: Wiersinga WM, Kahaly GJ, et al. Graves’ orbitopathy—a multidisciplinary approach, questions and answers. 2nd revised edition. Karger, Basel, Switzerland, pp 120–158

21.

Lanchu Yu, Oin Jiao Yu, Cheng Yanji Zhu, Lin Zhongjing, Shen Xi (2020) Evaluation of retinal and choroidal variations in thyroid-associated ophthalmopathy using optical coherence tomography angiography. BMC Ophthalmol. 20(1):421. https://doi.org/10.1186/s12886-020-01692-7CrossRef

22.

Jamshidian Tehrani M, Mahdizad Z, Kasaei A, Fard MA (2019) Early macular and peripapillary vasculature dropout in active thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 257(11):2533–2540. https://doi.org/10.1007/s00417-019-04442-8CrossRefPubMed

23.

Dave TV, Laghmisetty S, Krishnamurthy G, Bejjanki K, Ganguly A, Jonnadula GB, Dave VP, Reddy Pappuru R (2020) Retinal vascularity, nerve fiber, and ganglion cell layer thickness in thyroid eye disease on optical coherence tomography angiography. Orbit (Amsterdam, Netherlands) 17:1–8. https://doi.org/10.1080/01676830.2020.1846761

24.

Del Noce C, Vagge A, Nicolò M, Traverso CE (2020) Evaluation of choroidal thickness and choroidal vascular blood flow in patients with thyroid-associated orbitopathy (TAO) using SD-OCT and Angio-OCT. Graefes Arch Clin Exp Ophthalmol. 258(5):1103–1107. https://doi.org/10.1007/s00417-020-04616-9CrossRefPubMed

25.

Ye L, Zhou SS, Yang WL, Bao J, Jiang N, Min YL, Yuan Q, Tan G, Shen M, Shao Y (2018) Retinal microvasculature alteration in active thyroid-associated ophthalmopathy. Endocr Pract. 24(7):658–667. https://doi.org/10.4158/EP-2017-0229CrossRefPubMed

Title: Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT
Authors: Chiara Del Noce
Matilde Roda
Lorenzo Ferro Desideri
Carlo E. Traverso
Aldo Vagge
Publication date: 01-02-2022
Publisher: Springer Berlin Heidelberg
Keyword: Angiography
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2022
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-021-05336-4

2024 ASCO Annual Meeting

Springer Medicine

Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT

Abstract

Purpose

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2022

Correction to: An automatic approach for cell detection and segmentation of corneal endothelium in specular microscope

Prognosis and etiology of traumatic and non-traumatic corneal perforations in a tertiary referral hospital: a 30-year retrospective study

A novel tandem duplication of PRDM13 in a Chinese family with North Carolina macular dystrophy

Changes of retinal oxygen saturation during treatment of diabetic macular edema with a pre-defined regimen of aflibercept: a prospective study

Laser speckle flowgraphy findings in focal scleral nodule

Validation of a new objective method to assess lipid layer thickness without the need of an interferometer